TAKSTATM (CEM-102)
Fusidic acid (TAKSTATM, CEM-102) is an antibiotic with a long history of safety and efficacy outside the United States. Cempra has exclusive rights to the supply of the compound for the U.S. market. Fusidic acid is orally active against gram-positive bacteria, including all S. aureus strains such as HA-MRSA and CA-MRSA. A novel dosing regimen has been successfully evaluated in a Phase II trial in patients with acute bacterial skin and skin structure infections (aBSSSI). Cempra is conducting a Phase II trial of TAKSTA for patients with prosthetic joint infections.
Profile of TAKSTA (CEM-102)
Prosthetic joint infections (PJI) occur in about 1% of hip replacements and 2% of knee replacements, translating to an incidence rate of about 10,000 per year in the U.S. at current hip and knee arthroplasty rates. There are few good options to treat these serious staphylococcal, often MRSA infections, which require long-term antibiotic treatment. Current therapy in the U.S. is with intravenous antibiotics such as vancomycin. An oral drug that can be safely administered for a long period of time could improve care and quality of life for these patients.
TAKSTA has shown potent activity against a large number of S. aureus strains, including CA-MRSA, HA-MRSA and linezolid-resistant strains, isolated in the U.S over a 10 year period. Its broad S. aureus coverage makes it useful for a broad range of clinical applications. Because of its safety and tolerability profile, TAKSTA could be ideal for patients suffering from staphylococcal infections that require long-term therapy such as patients with PJIs.
Cempra has developed a unique oral loading dose regimen to optimize key pathogen coverage and minimize drug resistance development. This regimen is incorporated in our Phase II trial to treat PJIs with TAKSTA in combination with rifampin, which is commonly used with injectible antibiotics such as vancomycin to treat PJIs.
Research on TAKSTA
Publications
The links for the articles go to subscription-based sites and may require a fee to view the article.
Update on Fusidic Acid (CEM-102) Tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
R Jones, D Biedenbach, P Roblin, S Kohlhoff, M Hammerschlag
Antimicrobial Agents And Chemotherapy. October 2010 54: 4518-4519
http://aac.asm.org/cgi/content/citation/54/10/4518
Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. isolated in North America and Australia, 2007-2008
M. Castanheira, A.A. Watters, J.M. Bell, J.D. Turnidge, and R.N. Jones
Antimicrobial Agents and Chemotherapy September 2010 54: 3614-3617
http://www.ncbi.nlm.nih.gov/pubmed/20566766
Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102)
D Biedenbach, P Rhomberg, R Mendes, R Jones
Diagnostic Microbiology & Infectious Disease. March 2010 66: 301-307
http://www.dmidjournal.com/article/S0732-8893(09)00424-6/abstract
Performance of Fusidic Acid (CEM-102) Susceptibility Testing Reagents: Broth Microdilution, Disk Diffusion, and Etest Methods as Applied to Staphylococcus aureus
R Jones, M Castanheira, P Rhomberg, L Woosley, M Pfaller
Journal of Clinical Microbiology. March 2010 48: 972-976
http://jcm.asm.org/cgi/content/abstract/48/3/972
Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada
M Pfaller, M Castaneira, H Sader, R Jones
International Journal of Antimicrobial Agents. March 2010 35: 282-287
http://www.ijaaonline.com/article/S0924-8579(09)00510-X/abstract
Activity of Fusidic Acid Against Methicillin-resistant Staphylococcus Aureus (MRSA) Isolated from CF Patients
Prabhavathi Fernandes, Donald Anderson, K. Kosowska-Shick, P. McGhee, L. Beachel and P.C. Appelbaum
Download Abstract 
| Download Poster
sadfdsfsdaf sdfdsf dsf ds adsf dsf asd fasdf asdf asd fsdf dsf dsaf dasf asdf asdf sdf sdf sdfdsf dsf dsf sdf dsfds fdsf sdfsdfsdfsdf dsf sd fdsfsdf
fsg sdfgdfg sdfg sdfg fdgfdsg fsdgdfg fdsg fsdg
Evaluation of L6 Ribosomal Protein Alterations in Fusidic Acid-Resistant Staphylococcus aureus: Fitness Cost and Time Kill Analysis
M Castanheira, RN Jones, LN Woosley, RE Mendes, GJ Moet, DJ Farrell
Download Abstract
Fusidic Acid Activity and Coverage of Gram-positive Pathogens Associated with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the USA (2008-2010)
RN Jones, DJ Farrell, HS Sader, M Castanheira
Download Abstract | Download Poster
Activity of Fusidic Acid Tested Against Contemporary Staphylococcus aureus Collected from United States Hospitals
M. Castanheira, R.E. Mendes, P.R. Rhomberg, R.N. Jones
Download Abstract | Download Poster
Pharmacokinetics-Pharmacodynamics (PK-PD) of CEM- 102 (Sodium Fusidate) Against Streptococcus pyogenes Using In Vitro Pharmacodynamic Models (IVPM)
B. T. Tsuji, A. Forrest, P. A. Kelchlin, T. Brown, P. N. Holden, O. O. Okusanya, S. M. Bhavnani, P. Fernandes, P. G. Ambrose
Download Abstract | Download Poster
Activity of CEM-102 (sodium fusidate) against 40 MRSA from Cystic Fibrosis Patients
Cynthia Todd, Pamela Mcghee, and Peter Appelbaum
Download Abstract | Download Poster
Ability of CEM-102 (Fusidic Acid), Linezolid, Daptomycin to Select Resistant S.aureus Mutants at Steady-state Serum Levels
K. Kosowska-Shick, P. Mcghee, L. Beachel, P. C. Appelbaum;
Download Abstract | Download Poster
CEM-102 (Fusidic Acid) Maintains Potency against Resistant MRSA and Prevalent Hospital Acquired, Community Acquired,and Epidemic MRSA Clones
C.M. Pillar, M.K. Torres, D.F. Sahm and P. Fernandes
Download Abstract | Download Poster
In Vitro Activity Of Fusicic Acid (CEM-102) Against Resistant Strains Of Staphylococcus aureus
J. dubois, P. Fernandes
Download Abstract | Download Poster
Efficacy and Safety of CEM-102 in a Phase 2, Randomized, Double-Blind Study in Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
S. R. Moriarty, K. Clark, D. Scott, T. P. Degenhardt, P. Fernandes, J.C. Craft, G.R. Corey, J.G. Still; A Das
Download Abstract | Download Poster
CEM-102 (fusidic acid) in vitro activity and evaluation of molecular resistance mechanisms among European Gram-positive isolates, 2008-2009
M. Castanheira, D. Farrell, M. Janechek, R. Jones
Download Abstract | Download Poster
CEM-102 (Sodium Fusidate) Dosage Regimen Decision Support Using Population Pharmacokinetic (PPK) and Mechanism-Based Pharmacokinetic-Pharmacodynamic (PK-PD) Models
OO OKUSANYA, JB. BULITTA, A FORREST, BT TSUJI, SM BHAVNANI, J GORDON STILL, P FERNANDES, PG AMBROSE
Download Abstract
Contemporary Antimicrobial Activity of CEM-102 (Fusidic Acid [FA)]) Against Canadian Isolates of Staphylococci and Streptococci (2001-2006)
P. R. Rhomberg, L.N. Woosley, H.S. Sader, R. N. Jones
Download Abstract | Download Poster
Update on the Spectrum of CEM-102 (Fusidic Acid [FA)]) Against Contemporary Wildtype (WT) Bacterial Species Including Mutational Resistance (R) Analysis, and Synergy Testing
P. R. Rhomberg, R. E. Mendes, H. K. Becker, K. A. Fedler, H. S. Sader, R. N.
Download Abstract | Download Poster
Performance of CEM-102 (Fusidic Acid [FA)]) Susceptibility Testing Reagents; Broth Microdilution, Disk Diffusion and Etest Methods.
P. R. Rhomberg, L.N. Woosley, H.S. Sader, R. N. Jones
Download Abstract | Download Poster
Relevance of Protein Binding of CEM-102 (Fusidic acid) and its pH-dependent Effect on in vitro Activity
TP Degenhardt, PR Rhomberg, RN Jones, P Fernandes, D Johnson
Download Abstract | Download Poster
Contrasting Effect of Acidic pH on the Bactericidal Activities of CEM-102 (Fusidic Acid) vs. Linezolid and Clindamycin Towards Staphylococcus aureus
PM Tulkens, S Lemaire, F Van Bambeke
Download Abstract | Download Poster
Pharmacokinetics-Pharmacodynamics (PK-PD) of CEM-102 against Methicillin-Resistant Staphylococcus aureus (MRSA) using an In Vitro PD Model (IVPM) and Mechanism-Based (MB) Modeling
BT Tsuji, JB Bulitta, A Forrest, PA Kelchlin, T Brown, PN Holden, MP Pai, SM Bhavnani, P Fernandes, RN Jones, PG Ambrose
Download Abstract | Download Poster
Low CEM-102 (Fusidic Acid [FA]) Resistance (R) Rates and High Prevalence of Acquired (acq) Genes Among Staphylococcus spp. (SSP) from North America and Australia
M Castanheira, AA Watters, JM Bell, RN Jones, JD Turnidge
Download Abstract | Download Poster
Assessment of In Vivo Activity of CEM-102 (Fusidic Acid) in Murine Infection Models
T Murphy, S Little, R Wu, A Slee, P Fernandes
Download Abstract | Download Poster
Initial Quality Control (QC) Ranges for Fusidic Acid (FA) Using the CLSI Multi-Laboratory M23-A3 Study Design
RN Jones, JE Ross
Download Abstract | Download Poster
Population Pharmacokinetics (PPK) of CEM-102 in Healthy Subjects
JB Bulitta, OO Okusanya, A Forrest, SM Bhavnani, D Reynolds, MP Pai, JG Still, PB Fernandes, PG Ambrose
Download Abstract | Download Poster
Pharmacokinetics and Safety of Single, Multiple, and Loading Doses of CEM-102 in Healthy Subjects
JG Still, K Clark, TP Degenhardt, D Scott, P Fernandes, MJ Gutierrez
Download Abstract | Download Poster
From Mouse to Man: The Pharmacokinetics of CEM-102 (Fusidic acid)
TP Degenhardt, JG Still, K Clark, P Fernandes
Download Abstract | Download Poster